Tuesday, October 06, 2026 | 09:29 PM ISTहिंदी में पढें

Trump Pharma Tariffs

Nifty Pharma defies mkt slump, up 1% as select drugs exempt from US tariffs

Qualifying speciality medicines from India will be eligible for zero duty, providing some relief to Indian drugmakers with exposure to the US market.

Updated On : 29 Sep 2026 | 9:39 AM IST

Trump's 100% pharma tariff kicks in today, select Indian drugs get relief

Specified speciality drugs from India and 19 other jurisdictions qualify for zero duty as the US extends its 100% pharma tariff to more companies; generics remain outside its scope

Updated On : 29 Sep 2026 | 8:52 AM IST

US exempts India, 19 other nations from 100% tariff on speciality drugs

The US will not charge any ad valorem tariff on certain speciality drugs and associated ingredients used for treatment of rare medical conditions imported from India and 19 other countries. An ad valorem tariff is a set percentage of the monetary value of the goods to be taxed, according to the World Customs Organisation. The US Commerce Department published the list of countries in the Federal Register as it prepares to impose a 100 per cent tariff on certain patented pharmaceutical imports and their associated ingredients from September 29. On April 2, President Donald Trump issued a proclamation to impose tariffs on imports of patented pharmaceuticals, biologics, and associated ingredients into the US as part of efforts to encourage domestic production. Eligible products for the zero per cent tariff rate include all drugs designated for rare diseases, infertility treatments, cell therapies, gene therapies, antibody-drug conjugates (ADCs), and animal pharmaceuticals. Components o

Updated On : 29 Sep 2026 | 7:55 AM IST

Indian drugmakers in no rush to shift to US despite tariff threat

Indian pharma companies are expanding selectively in the US for complex products while retaining India as their manufacturing base despite Trump's tariff threat

Updated On : 03 Aug 2026 | 5:08 AM IST

Dr Reddy's Labs shares tank 9% to 52-week low after Q1 show. Time to sell?

Brokerages largely remain bearish on Dr Reddy's Labs shares following the Q1 earnings show.

Updated On : 23 Jul 2026 | 10:59 AM IST

Trump's 200% tariffs on imported generic medicines to test India's edge

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

Updated On : 22 Jul 2026 | 11:37 PM IST

US proposal to impose tariffs on generic medicines could impact India: GTRI

The proposed steep tariffs announced by the US on generic medicines could significantly affect India's largest pharmaceutical export market, economic think tank GTRI said on Wednesday. However, it said that the impact is unlikely to be uniform. "Many Indian generic medicines sell for seven to ten times less than branded alternatives. Even after a 100 per cent tariff, many products could remain cheaper than branded medicines, meaning much of the additional cost would likely be passed on to US healthcare providers, insurers and patients rather than immediately eliminating Indian exports," it said. It added that the greatest pressure is expected to fall on higher-value generic formulations and branded generics, where manufacturing in the United States could become commercially viable. "The proposed tariffs could significantly affect India's largest pharmaceutical export market," Global Trade Research Initiative (GTRI) founder Ajay Srivastava said, adding that India should also reduce